Moses Austin

Carine Schneider and Tom Wilkinson Join LogicMark’s Board of Directors to Help Accelerate Growth

Retrieved on: 
Tuesday, October 31, 2023

Ms. Schneider and Mr. Wilkinson both bring decades of financial services, international business, and consulting experience.

Key Points: 
  • Ms. Schneider and Mr. Wilkinson both bring decades of financial services, international business, and consulting experience.
  • “I am thrilled to welcome Carine and Tom to our Board of Directors.
  • Ms. Schneider also served on the Board of Directors of Certent, Global Shares and AST Private Company Solutions.
  • “I’m thrilled to join LogicMark during this pivotal moment in the care economy,” said Mr. Wilkinson.

NTT Research CIS Lab Director Receives Fourth Test-of-Time Award

Retrieved on: 
Monday, November 6, 2023

NTT Research, Inc. , a division of NTT (TYO:9432), today announced that a paper co-authored by Cryptography & Information Security (CIS) Lab Director Brent Waters has won an IEEE Symposium on Foundations of Computer Science (FOCS) Test of Time Award .

Key Points: 
  • NTT Research, Inc. , a division of NTT (TYO:9432), today announced that a paper co-authored by Cryptography & Information Security (CIS) Lab Director Brent Waters has won an IEEE Symposium on Foundations of Computer Science (FOCS) Test of Time Award .
  • In addition, two papers co-authored by scientists from the CIS Lab and the NTT Social Informatics Laboratories (SIL) will be presented at this year’s conference.
  • “The FOCS 2013 paper changed the landscape of theoretical cryptography,” CIS Lab Senior Scientist Abhishek Jain said.
  • Takashi Yamakawa, a Distinguished Researcher at NTT SIL, focuses on constructions of post-quantum and quantum cryptographic protocols and their security.

Laura Chow, MD, Cancer Immunotherapy Trailblazer, Joins Summit as Senior Vice President of Clinical Development

Retrieved on: 
Thursday, November 2, 2023

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Therapeutics as Senior Vice President of Clinical Development.
  • We are very excited to welcome Laura to our team.”
    Dr. Chow remains in active clinical practice as a medical oncologist specialized in lung and head and neck cancers.
  • She joins Summit from Fate Therapeutics, where she was the Vice President of Clinical Development in Solid Tumors.
  • Chow’s experience being on the ground floor of cancer immunotherapy is unmatched,” added Dr. Allen S. Yang, Chief Medical Officer at Summit.

Blue Bird Appoints Two Vice Presidents Amid Company’s Continued Growth

Retrieved on: 
Wednesday, November 1, 2023

Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, today announced the appointment of two new vice presidents with immediate effect.

Key Points: 
  • Blue Bird Corporation (Nasdaq: BLBD), the leader in electric and low-emission school buses, today announced the appointment of two new vice presidents with immediate effect.
  • Blue Bird expanded its leadership ranks as it continues to grow its zero- and low-emissions product portfolio and strategic supplier base.
  • Prior to joining Blue Bird, Burleigh worked for Ford Motor Company for 15 years in sales and customer support roles.
  • “I am pleased to appoint two outstanding Blue Bird executives – Albert Burleigh and Jeff VanAssche – to the rank of vice president,” said Phil Horlock, CEO of Blue Bird Corporation.

Endeavor BioMedicines Appoints Paul Frohna, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 2, 2023

Endeavor BioMedicines , a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.

Key Points: 
  • Endeavor BioMedicines , a clinical-stage company developing therapies for of fibrotic disease and oncology, today announced the appointment of Paul Frohna, M.D., Ph.D., as its Chief Medical Officer.
  • “We’re pleased to welcome Paul as our Chief Medical Officer, and we look forward to his leadership as we progress our pipeline of therapies for patients with fibrosis and cancer,” said John Hood, Ph.D., Co-Founder, CEO and Chairman, Endeavor BioMedicines.
  • “It is a privilege to join Endeavor as the company enters its next stage of growth," said Dr. Frohna.
  • He has successfully designed and initiated translational and clinical programs for biologics, small molecules and stem cells across multiple therapeutic areas.

Boy Scouts of America Selects Roger Krone as New President and Chief Executive Officer

Retrieved on: 
Friday, November 3, 2023

IRVING, Texas, Nov. 3, 2023 /PRNewswire/ -- Following an extensive selection process, the Boy Scouts of America has chosen Roger A. Krone to serve as its next President and Chief Executive Officer.

Key Points: 
  • IRVING, Texas, Nov. 3, 2023 /PRNewswire/ -- Following an extensive selection process, the Boy Scouts of America has chosen Roger A. Krone to serve as its next President and Chief Executive Officer.
  • "As a life-long Scout, the opportunity to lead the Scouting movement represents the perfect capstone to a long and fruitful career and a chance to give back," said Krone.
  • In late October, the Chief Scout Executive Selection Committee unanimously selected Krone to present to the BSA's National Executive Committee and National Board.
  • "Leading the restructuring process was exceptionally challenging, and Roger demonstrated unwavering determination and resolve throughout.

Anheuser-Busch, MADD, and Uber Partner with Brown Distributing of Texas to Encourage 21+ Fans to 'Decide to Ride' by Planning Ahead for Sober Rides on Game Days

Retrieved on: 
Thursday, November 2, 2023

ST. LOUIS, Nov. 2, 2023 /PRNewswire/ -- The country's leading brewer, Anheuser-Busch, the nation's largest drunk driving victim services and advocacy nonprofit, Mothers Against Drunk Driving (MADD), and ridesharing platform, Uber, are bringing their first-of-its-kind coalition to college communities this fall. As a part of the next phase of the Decide to Ride campaign, the coalition is teaming up with Anheuser-Busch wholesaler partner Brown Distributing to help combat drunk driving during the University of Texas Longhorns' 2023 football season. 

Key Points: 
  • This joint effort will meet 21+ fans in the stands to raise awareness and promote road safety by providing educational and ridesharing opportunities, including some locally available discounts on Uber rides.
  • To ensure a future with more cheers for all, it's imperative that we help college football fans get home safely.
  • Brown Distributing has also set up an Uber voucher program to provide $10 off rides around DKR Texas Memorial Stadium throughout the weekend.
  • Ahead of the fall football season, we want to make it easy for everyone to Decide to Ride."

Aileron Therapeutics Announces Acquisition of Lung Therapeutics

Retrieved on: 
Tuesday, October 31, 2023

WALTHAM, Mass. and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments. Immediately following the acquisition of Lung Tx, Aileron entered into a definitive agreement for the sale of shares of Aileron's Series X non-voting convertible preferred stock (the "Series X preferred stock") and warrants to purchase shares of Aileron's common stock in a private placement to a group of accredited investors led by Bios Partners ("Bios"), and including Nantahala Capital, as well as additional undisclosed investors. The private placement is expected to result in gross proceeds to Aileron of approximately $18 million before deducting placement agent fees and other offering expenses. Aileron intends to use the proceeds from the private placement primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of IPF, and for general corporate purposes. 

Key Points: 
  • and AUSTIN, Texas, Oct. 31, 2023 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN) today announced it has acquired Lung Therapeutics, Inc. ("Lung Tx"), a privately held biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications that have no approved or limited effective treatments.
  • "We are pleased to announce that after a thorough evaluation of strategic alternatives, we have completed the acquisition of Lung Therapeutics, which we believe represents a value-creation opportunity for Aileron's stockholders.
  • "Lung Therapeutics has built a promising clinical-stage pipeline for life-threatening lung conditions, and we believe in the ability of our combined companies to deliver value to both patients and stockholders."
  • I want to thank the board and entire team of Lung Therapeutics for all their hard work with this transaction."

Proactive Worldwide Welcomes Two Strategic Hires to Enhance Its Competitive Intelligence Operations

Retrieved on: 
Monday, October 30, 2023

SCHAUMBURG, Ill., Oct. 30, 2023 /PRNewswire/ -- In a strategic move to accommodate the increased demand for their competitive research and analysis services, Proactive Worldwide (PWW) is thrilled to announce the onboarding of two new senior analysts, Heather Yoder and Avery Ekman. These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.

Key Points: 
  • These latest hires reflect PWW's commitment to offer the finest expertise in the competitive intelligence sector.
  • Dr. Heather Yoder shifted from the medical field into the realm of pharmaceutical competitive intelligence.
  • Her experience spans over 10 years, with remarkable achievements in primary and secondary research, analysis, as well as project management.
  • Their combined expertise will further ensure that our clients continue to receive actionable insights and value, backed by extensive research and analysis."

Kayla Oliver Joins Austin Office of Appellate Firm Alexander Dubose & Jefferson

Retrieved on: 
Monday, October 30, 2023

AUSTIN, Texas, Oct. 30, 2023 /PRNewswire/ -- The Texas appellate firm Alexander Dubose & Jefferson LLP (ADJ) is pleased to announce the addition of Kayla Oliver to the firm's Austin office.

Key Points: 
  • AUSTIN, Texas, Oct. 30, 2023 /PRNewswire/ -- The Texas appellate firm Alexander Dubose & Jefferson LLP (ADJ) is pleased to announce the addition of Kayla Oliver to the firm's Austin office.
  • She currently teaches an advanced appellate writing course as an adjunct professor of legal writing at the University of Texas School of Law.
  • Before joining ADJ, Ms. Oliver founded Law Review, LLC, a legal writing consulting firm that offers editing, drafting and coaching services to lawyers in state and federal courts across the country.
  • "I am thrilled at the opportunity to practice with the attorneys of Alexander Dubose & Jefferson," said Ms. Oliver.